Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Prostate Cancer Research

Study Title:  RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer:  A Phase III Randomized Trial (Identifier: NCT01368588)

Principal Investigator: Krishna Reddy, M.D.

Study Purpose:  This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancerAndrogens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

Study Coordinator:  For more information email Stephanie Smiddy, RN or call 419.383.6962.


Study Title:  NRG-GU002:  Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel.  (Identifier: NCT03070886)

Principal Investigator: Siddharth Saraiya, M.D.

Study Purpose:  This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.

Study Coordinator:  For more information email Stephanie Smiddy, RN or call 419.383.6962.


Study Title:   HERO:  A Multinational Phase 3 Randomized, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer. (Identifier: NCT03085095)

Principal Investigator: David Elliott, M.D.

Study Purpose:  The purpose of this study is to determine the benefit and safety of relugolix 120 mg once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (<=50 ng/dL [1.7 nmol/L] in patients with androgen-sensitive advanced prostate cancer.

Study Coordinator:  For more information email Stephanie Smiddy, RN or call 419.383.6962.


 

Last Updated: 10/11/17